T0	Outcomes 1026 1046	both groups attained
T1	Outcomes 1199 1210	had greater
T2	Outcomes 1250 1275	-1.79% (0.05); p = 0.019]
T3	Outcomes 1385 1494	liraglutide group reported a greater number of gastrointestinal treatment-emergent adverse events (p < 0.001)
T4	Outcomes 1561 1590	-3.0 (3.6) kg for liraglutide